| Title： | Guidelines on SARS-CoV-2 vaccination and prevention in kidney transplant recipients in China |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Prevention |
| Countries and regions： | China |
| Guidelines users： | Medical staff engaged in clinical work of kidney transplantation |
| Evidence classification method： | This guide uses the 2009 Oxford University Evidence Grading System to rate the strength of the supporting evidence for recommendations The level of evidence is specifically described A 1a Systematic review of randomized controlled studies 1b Randomized controlled studies with small confidence intervals 1c shows any evidence of "all or no effect" A systematic review of B2a cohort studies 2b Single cohort study 2c Study based on patient outcomes 3a Systematic review of case-control studies 3b Single case control study 4 Case series reports, low-quality cohort studies, and low-quality case-control studies D 5 Expert opinion. |
| Development unit： | Branch of Organ Transplantation, Chinese Medical Association |
| Registration time: | 2024-04-24 |
| Registration number： | PREPARE-2024CN581 |
| Purpose of the guideline: | Based the latest published data at home and abroad, this guideline updates relevant recommendations and forms guidelines on the vaccination and prevention of novel coronavirus among kidney transplant recipients. To provide reference for clinicians and health care workers. |
